<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484145</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-10</org_study_id>
    <nct_id>NCT01484145</nct_id>
  </id_info>
  <brief_title>Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail</brief_title>
  <official_title>An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how much terbinafine is delivered to the nail bed
      after treatment with a number of modifications to a previously studied method for
      iontophoretic delivery of terbinafine gel. Iontophoretic delivery involves the use of a small
      electric charge to deliver drug across skin and nails.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of terbinafine in the nail bed (ng/mg)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma terbinafine levels (ng/ml)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (AEs)&amp; Serious Adverse Events (SAEs)</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>6 mA.min, 20 mins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mA/min, 20 mins, clamping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mA/min, 20 mins, debridement, clamping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mA/min, 30 mins, clamping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mA/min, 50 mins, debridement, clamping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine HCl</intervention_name>
    <description>4% w/w terbinafine HCL gel, single dose,</description>
    <arm_group_label>6 mA.min, 20 mins</arm_group_label>
    <arm_group_label>6 mA/min, 20 mins, clamping</arm_group_label>
    <arm_group_label>6 mA/min, 20 mins, debridement, clamping</arm_group_label>
    <arm_group_label>15 mA/min, 30 mins, clamping</arm_group_label>
    <arm_group_label>15 mA/min, 50 mins, debridement, clamping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive KOH

          -  25-75% involvement of the visible nail.

          -  Nail plate must be &lt; 3 mm thick.

          -  Must have signed informed consent.

          -  Must agree to avoid any type of pedicure or application of any nail polish product or
             nail cosmetic to the toenails after the screening visit until Day 28.

          -  Female subjects of childbearing potential must agree to take measures to avoid
             pregnancy until the day after Day 28

          -  Must agree to avoid the use of oral antifungals or topical terbinafine anywhere on the
             body until the day after Day 28. Topical antifungals other than terbinafine can be
             used on the body other than the feet after Day 0.

        Exclusion Criteria:

          -  Presence of proximal subungual onychomycosis or white superficial onychomycosis

          -  Fungal involvement of a majority of the lunula

          -  Subjects with psoriasis, eczema, or other abnormalities that could result in a
             clinically abnormal nail

          -  Presence of dermatophytoma or onychomycotic spikes or exclusively lateral groove
             involvement

          -  Traumatized or dystrophic target great toenail.

          -  Known diabetics

          -  Subjects with peripheral vascular disease

          -  Subjects who are immunosuppressed (chronic corticosteroid therapy, solid organ or bone
             marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or
             planned within the next 12 months), or HIV infection.

          -  Use of systemic corticosteroids within 30 days preceding Day 0

          -  Use of topical antifungals on the feet in the preceding 30 days of Day 0 through Day
             28

          -  Use of topical terbinafine in the 30 days prior to treatment through Day 28

          -  Use of systemic antifungals in the preceding 120 days of Day 0 through Day 28

          -  Use of any investigational drug(s) within 30 days (120 days for systemic antifungals)
             preceding Day 0 through Day 28

          -  Has previously participated in this study

          -  Is pregnant or is a nursing mother

          -  Women of of child bearing potential who are not using an adequate form of
             contraception (or abstinence)

          -  Subjects with pacemakers/automatic implantable cardioverter/defibrillators

          -  Subjects with an implantable electronic device.

          -  Subjects with a bleeding disorder or who are using warfarin or any other blood
             coagulation modulator including aspirin in the 14 days prior to treatment through Day
             28
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Nail fungus</keyword>
  <keyword>Tinea Unguium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

